Cargando…

Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir

Recurrent respiratory papillomatosis is a viral induced disease characterised by exophytic epithelial lesions affecting the larynx. The problem with its treatment is the high recurrence of papilloma growth after surgical removal. The aim of our review is to analyse the actual use of cidofovir, an ag...

Descripción completa

Detalles Bibliográficos
Autores principales: FUSCONI, M., GRASSO, M., GRECO, A., GALLO, A., CAMPO, F., REMACLE, M., TURCHETTA, R., PAGLIUCA, G., DE VINCENTIIS, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pacini Editore SpA 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346993/
https://www.ncbi.nlm.nih.gov/pubmed/25762828
_version_ 1782359775621677056
author FUSCONI, M.
GRASSO, M.
GRECO, A.
GALLO, A.
CAMPO, F.
REMACLE, M.
TURCHETTA, R.
PAGLIUCA, G.
DE VINCENTIIS, M.
author_facet FUSCONI, M.
GRASSO, M.
GRECO, A.
GALLO, A.
CAMPO, F.
REMACLE, M.
TURCHETTA, R.
PAGLIUCA, G.
DE VINCENTIIS, M.
author_sort FUSCONI, M.
collection PubMed
description Recurrent respiratory papillomatosis is a viral induced disease characterised by exophytic epithelial lesions affecting the larynx. The problem with its treatment is the high recurrence of papilloma growth after surgical removal. The aim of our review is to analyse the actual use of cidofovir, an agent used in adjuvant therapy. We have reviewed 6 manuscripts that included a total of 118 patients. The parameters taken into account were: concentration of infiltrated cidofovir (mg/ml), therapeutic response, relapse-free time (months), side effects, genotypes (HPV-6/11/18) and evolution of dysplasia. Cidofovir was injected at concentrations from 2.5 to 15 mg/ml, therapeutic response was from 56.25% to 82.3% and relapse-free time was from 10.05 to 49 months. There were 2 cases of dysplasia during therapy. Ten patients had been infected by HPV-6, 4 patients by HPV-11 and 10 patients by HPV-6 and HPV-11. The purposes of our review include the following: to stress that the juvenile form is more aggressive than other forms, to demonstrate than the drug has good adjuvant action although it does not significantly change the final response to the disease, to show that side effects are modest and, finally, to disprove the hypothesis that cidofovir may promote evolution towards dysplasia. In conclusion, combination of surgical removal and injection of cidofovir is associated with good response in recurrent respiratory papillomatosis.
format Online
Article
Text
id pubmed-4346993
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Pacini Editore SpA
record_format MEDLINE/PubMed
spelling pubmed-43469932015-03-11 Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir FUSCONI, M. GRASSO, M. GRECO, A. GALLO, A. CAMPO, F. REMACLE, M. TURCHETTA, R. PAGLIUCA, G. DE VINCENTIIS, M. Acta Otorhinolaryngol Ital Review Recurrent respiratory papillomatosis is a viral induced disease characterised by exophytic epithelial lesions affecting the larynx. The problem with its treatment is the high recurrence of papilloma growth after surgical removal. The aim of our review is to analyse the actual use of cidofovir, an agent used in adjuvant therapy. We have reviewed 6 manuscripts that included a total of 118 patients. The parameters taken into account were: concentration of infiltrated cidofovir (mg/ml), therapeutic response, relapse-free time (months), side effects, genotypes (HPV-6/11/18) and evolution of dysplasia. Cidofovir was injected at concentrations from 2.5 to 15 mg/ml, therapeutic response was from 56.25% to 82.3% and relapse-free time was from 10.05 to 49 months. There were 2 cases of dysplasia during therapy. Ten patients had been infected by HPV-6, 4 patients by HPV-11 and 10 patients by HPV-6 and HPV-11. The purposes of our review include the following: to stress that the juvenile form is more aggressive than other forms, to demonstrate than the drug has good adjuvant action although it does not significantly change the final response to the disease, to show that side effects are modest and, finally, to disprove the hypothesis that cidofovir may promote evolution towards dysplasia. In conclusion, combination of surgical removal and injection of cidofovir is associated with good response in recurrent respiratory papillomatosis. Pacini Editore SpA 2014-12 /pmc/articles/PMC4346993/ /pubmed/25762828 Text en © Copyright by Società Italiana di Otorinolaringologia e Chirurgia Cervico-Facciale http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License, which permits for noncommercial use, distribution, and reproduction in any digital medium, provided the original work is properly cited and is not altered in any way. For details, please refer to http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Review
FUSCONI, M.
GRASSO, M.
GRECO, A.
GALLO, A.
CAMPO, F.
REMACLE, M.
TURCHETTA, R.
PAGLIUCA, G.
DE VINCENTIIS, M.
Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir
title Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir
title_full Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir
title_fullStr Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir
title_full_unstemmed Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir
title_short Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir
title_sort recurrent respiratory papillomatosis by hpv: review of the literature and update on the use of cidofovir
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346993/
https://www.ncbi.nlm.nih.gov/pubmed/25762828
work_keys_str_mv AT fusconim recurrentrespiratorypapillomatosisbyhpvreviewoftheliteratureandupdateontheuseofcidofovir
AT grassom recurrentrespiratorypapillomatosisbyhpvreviewoftheliteratureandupdateontheuseofcidofovir
AT grecoa recurrentrespiratorypapillomatosisbyhpvreviewoftheliteratureandupdateontheuseofcidofovir
AT galloa recurrentrespiratorypapillomatosisbyhpvreviewoftheliteratureandupdateontheuseofcidofovir
AT campof recurrentrespiratorypapillomatosisbyhpvreviewoftheliteratureandupdateontheuseofcidofovir
AT remaclem recurrentrespiratorypapillomatosisbyhpvreviewoftheliteratureandupdateontheuseofcidofovir
AT turchettar recurrentrespiratorypapillomatosisbyhpvreviewoftheliteratureandupdateontheuseofcidofovir
AT pagliucag recurrentrespiratorypapillomatosisbyhpvreviewoftheliteratureandupdateontheuseofcidofovir
AT devincentiism recurrentrespiratorypapillomatosisbyhpvreviewoftheliteratureandupdateontheuseofcidofovir